ASHLEY BOLES: Open Payments
NPI 1578003596 · LAWRENCEBURG, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$511 in 28 payments from 14 companies in 2025. Trend: 2023 $883 · 2024 $780 · 2025 $511
Food & beverage: $511
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $92 |
| Novo Nordisk Inc | 4 | $68 |
| AstraZeneca Pharmaceuticals LP | 3 | $51 |
| Amgen Inc. | 3 | $48 |
| Exact Sciences Corporation | 2 | $41 |
| Lilly USA, LLC | 2 | $36 |
| GlaxoSmithKline, LLC. | 2 | $35 |
| PFIZER INC. | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
Products named: Ozempic, UBRELVY, REXULTI, Cologuard Collection Kit, QULIPTA, BEVESPI AEROSPHERE, MOUNJARO, TRELEGY ELLIPTA.
Industry payments across IN — which companies pay providers there.
